Corcept director plans $3.3M stock sale

Corcept Therapeutics Incorporated (CORT) received a Rule 144 notice from director Kimberly Park regarding a planned sale of common stock.

Rhea-AI Filing Summary

Corcept Therapeutics Incorporated (CORT) received a Rule 144 notice from director Kimberly Park regarding a planned sale of common stock. The notice covers 26,685 shares of Corcept common stock to be sold through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $3,270,169.36, based on an issuer share count of 108,098,397 shares. The proposed sale date and related stock option exercise are listed as 08/26/2026, with cash payment for the option exercise and trading on NASDAQ.

Key Figures

Shares to be sold: 26,685 shares Aggregate market value: $3,270,169.36 Shares outstanding: 108,098,397 shares +1 more

4 metrics

Shares to be sold 26,685 shares Common stock covered by the Rule 144 notice for Kimberly Park

Aggregate market value $3,270,169.36 Value associated with 26,685 shares of Corcept common stock

Shares outstanding 108,098,397 shares Corcept Therapeutics common stock outstanding as reported in the notice

Proposed sale date 08/26/2026 Date for securities to be sold and stock option exercise

Key Terms

Rule 144, Stock Option Exercise, Aggregate market value, NASDAQ

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Stock Option Exercise financial

"Common | 08/26/2026 | Stock Option Exercise | Issuer"

A stock option exercise is the act of using a previously granted right to buy shares of a company's stock at a specific, predetermined price by paying that price and receiving the shares. It matters to investors because exercising changes who owns the shares (which can dilute existing ownership), can trigger taxable events and shift potential gains or losses, and affects voting power and the company’s outstanding share count—like turning a voucher into an actual product that becomes part of circulating supply.

Aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC Executive Financial Services ... | 3270169.36"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

NASDAQ market

"108098397 | 08/26/2026 | NASDAQ"

The Nasdaq is a stock exchange where many companies' shares are bought and sold, functioning much like a marketplace for investments. It matters to investors because it provides a platform to buy and sell ownership stakes in companies, helping them track the value of those companies and make informed decisions. As one of the largest and most technology-focused markets, it also reflects trends and developments in the business world.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for CORCEPT THERAPEUTICS INC (CORT)?

It discloses that director Kimberly Park has filed a Rule 144 notice for a planned sale of 26,685 shares of Corcept common stock, linked to a stock option exercise, with an indicated aggregate market value of $3,270,169.36.

How many CORT shares are covered by Kimberly Park’s planned Rule 144 sale?

The notice covers 26,685 shares of Corcept Therapeutics common stock to be sold through Morgan Stanley Smith Barney LLC, as reported in the Form 144 filing.

What aggregate market value is associated with the CORT shares in this Form 144?

The Form 144 lists an aggregate market value of $3,270,169.36 for the 26,685 shares of Corcept Therapeutics common stock covered by the planned Rule 144 sale.

What is the proposed sale date in the CORT Form 144 filed by Kimberly Park?

The proposed sale date reported is 08/26/2026, which is also the listed date for the related stock option exercise and the securities to be sold.

How many Corcept Therapeutics (CORT) shares are reported outstanding in the Form 144?

The filing states that Corcept Therapeutics has 108,098,397 shares of common stock outstanding, which provides context for the size of the planned 26,685-share sale.

Through which broker and market is the CORT Rule 144 sale expected to occur?

The shares are to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with the security identified as trading on NASDAQ.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/26/2026 - 04:15 PM EDT Accepted by SEC EDGAR 08/26/2026 - 04:14 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001788208
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CORCEPT THERAPEUTICS INCORPORATED
SEC File Number	000-50679
Address of Issuer	101 Redwood Shores Parkway Redwood City CALIFORNIA 94065
Phone	650-327-3270
Name of Person for Whose Account the Securities are To Be Sold	KIMBERLY PARK
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	26685	3270169.36	108098397	08/26/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/26/2026	Stock Option Exercise	Issuer			26685	08/26/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/26/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Kimberly Park
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)